(60), T cell proportion in 188 DLBCL patients (median, 16%) by fluorescent mIHC was comparable to that in our mIHC study (18), and high proportions of TIM3+, LAG3+, and/or PD-1+ T cells were associated with poor clinical outcome in one to two of the two DLBCL cohorts (60). The gene discussed is HAVCR2; the disease is diffuse large B-cell lymphoma.